National Institutes of Health, a Component of the US Dept. of Health & Human Services

University of Washington

Columbia University

Altor Bioscience Corporation

Sanofi

The United States of America, As Represented by the Secretary, Departmen

Mark Connors

John R Mascola

Peter D Kwong

Gary J Nabel

Tongqing Zhou

Baoshan Zhang

Ivelin Georgiev

Zhi-yong Yang

Xueling Wu

Yongping Yang

Jinghe Huang

Rebecca S Rudicell

Jiang Zhu

Gwo-Yu Chuang

Young Do Kwon

Gilad Ofek

Richard Wyatt

William Ray Schief

Wei Shi

Richard Schwartz

John Mascola

Peter Rhode

Ercole Rao

Christian Lange

Jochen Kruip

Christian Beil

Ling Xu

Zhi-Yong Yang

Mario Roederer

Jochen Beninga

Wulf Dirk Leuschner

Yuxing Li

Carl-Magnus Hogerkorp

Leo Laub

Lawrence Shapiro

Tatyana Gindin

Krisha McKee

Sijy O'Dell

Robert Bailer

Mark Louder

Mangaiarkarasi Asokan

Jonathan Cooper

Lisa Kueltzo

Amarendra Pegu

Michael Bender

Kevin Carlton

Byong Ha Kang

Elise Ishida

Anqi Zheng

Nicole Amy Doria-Rose

Nancy Longo

Stephen Migueles

Gary Nabel

Leo B Laub

William R Schief

Richard A Koup

Ronnie Wei

Nicole A Doria-rose

Engineered TCR molecules specific to retroviral peptide/HLA complexes guide direct killing and/or enable robust immune responses against HIV infected cells. In a first aspect, a TCR fusion polypeptide comprises a TCR variable alpha (Vα) domain, a TCR variable beta domain (Vβ) and a TCR constant region domain (C), wherein the TCR fusion polypeptide is specific for HIV peptides.

Human immunodeficiency virus-specific T cell receptors

Antibodies and antigen binding fragments that specifically bind to gp120 and neutralize HIV-1 are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting HIV-1 using these antibodies are disclosed. In addition, the use of these antibodies, antigen binding fragment, nucleic acids and vectors to prevent and/or treat an HIV-1 infection is disclosed.

Neutralizing antibodies to GP120 and their use

Neutralizing antibodies that specifically bind to HIV-1 Env and antigen binding fragments of these antibodies are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting HIV-1 using these antibodies are disclosed. In addition, the use of these antibodies, antigen binding fragment, nucleic acids and vectors to prevent and/or treat an HIV-1 infection is disclosed.

10E8 neutralizing antibody variants that bind to the MPER region of HIV-1 GP41 and their use

Neutralizing antibodies to HIV-1 GP41 and their use

Monoclonal neutralizing antibodies that specifically bind to HIV-1 gp120 and antigen binding fragments of these antibodies are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting HIV using these antibodies are disclosed. In addition, the use of these antibodies, antigen binding fragment, nucleic acids and vectors to prevent and/or treat an HIV infection is disclosed.

Broadly neutralizing HIV-1 antibodies that bind to the CD4-binding site of the envelope protein

Neutralizing antibodies to gp120 and their use

Monoclonal neutralizing antibodies are disclosed that specifically bind to the HIV-1 gp41 membrane-proximal external region (MPER). Also disclosed are compositions including the disclosed antibodies that specifically bind gp41, nucleic acids encoding these antibodies, expression vectors including the nucleic acids, and isolated host cells that express the nucleic acids. The antibodies and compositions disclosed herein can be used for detecting the presence of HIV-1 in a biological sample, or detecting an HIV-1 infection or diagnosing AIDS in a subject. In additional, the broad neutralization breadth of the disclosed antibodies makes them ideal for treating a subject with an HIV infection. Thus, disclosed are methods of treating and/or preventing HIV infection.

Neutralizing GP41 antibodies and their use

Broadly neutralizing HIV-1 VRC07 antibodies that bind to the CD4-binding site of the envelope protein

Monoclonal neutralizing antibodies are disclosed that specifically bind to the CD4 binding site of HIV-1 gp120. Monoclonal neutralizing antibodies also are disclosed that specifically bind to HIV-1 gp41. The identification of these antibodies, and the use of these antibodies are also disclosed. Methods are also provided for enhancing the binding and neutralizing activity of any antibody using epitope scaffold probes.

Neutralizing antibodies to HIV-1 and their use

Growing community of inventors

Bethesda, MD, United States of America

Mark Connors